pharvaris

About

We're a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help people living with hereditary angioedema (HAE) and other bradykinin-mediated diseases. Our team reunites many of the experts responsible for the discovery and approval of icatibant, an earlier HAE treatment. We're advancing potent, orally available compounds targeting this clinically proven therapeutic target, working to provide new alternatives to injected therapies for all sub-types of HAE. Our mission is to set people living with HAE free from angioedema symptoms and attacks, freedom from injections, and injectable-like efficacy with a well-tolerated profile in oral therapies. We're currently advancing two pivotal Phase 3 studies of our investigational drug deucrictibant for both prophylactic and on-demand treatment of HAE attacks. Our culture is built on core values of considering others carefully, leading with trust, ensuring rigor and diversity of thought, and contributing freely. We're driven by individuals committed to developing breakthrough therapies that can make a real difference in patients' lives.